Vatalanib free base is primarily used in research and clinical settings as a potent inhibitor of vascular endothelial growth factor receptors (VEGFRs). It is studied for its potential to inhibit angiogenesis, the process by which new blood vessels form, which is crucial in the growth and spread of tumors. By targeting VEGFRs, it aims to cut off the blood supply to cancerous tissues, thereby slowing tumor progression. This compound has been explored in clinical trials for treating various cancers, including colorectal cancer and glioblastoma. Its application extends to understanding molecular pathways involved in angiogenesis and developing targeted cancer therapies.